Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 2, Issue 7, Pages 703-714Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2.7.703
Keywords
graft-versus-malignancy; haematopoietic stem cell transplant; non-myeloablative
Funding
- NCI NIH HHS [CA15704, CA18221, CA78902, P01 CA078902, CA18029] Funding Source: Medline
- NHLBI NIH HHS [HL36444] Funding Source: Medline
Ask authors/readers for more resources
Reduced intensity conditioning regimens prior to allogeneic haematopoietic stem cell transplantation (HSCT) were first described in the 1970s, and have developed rapidly over the past few years to become an important consideration as immunological therapy for patients with haematological and selected solid organ malignancies. This is especially the case for patients considered ineligible for conventional allogeneic HSCT due to age or medical contraindications. With the development of minimally toxic conditioning regimens, additional potential applications include the provision of normal haematopoietic repopulating cells to patients who have an inherited gene defect such as an haemoglobinopathy or an inborn error of metabolism. Intensive investigation in stem cell research promises to provide dramatic new insights into human biology, paving the way for new therapeutic approaches to malignant and inherited disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available